CASPR2 autoimmunity in children expanding to mild encephalopathy with hypertension

• Verfasst von: Syrbe, Steffen [VerfasserIn]
• Verfasst von: Stettner, Georg M. [VerfasserIn]
• Verfasst von: Bally, Julien [VerfasserIn]
• Verfasst von: Borggraefe, Ingo [VerfasserIn]
• Verfasst von: Bien, Corinna I. [VerfasserIn]
• Verfasst von: Ferfoglia, Ruxandra Iancu [VerfasserIn]
• Verfasst von: Huppke, Peter [VerfasserIn]
• Verfasst von: Kern, Jan [VerfasserIn]
• Verfasst von: Polster, Tilman [VerfasserIn]
• Verfasst von: Probst-Müller, Elisabeth [VerfasserIn]
• Verfasst von: Schmid, Silvia [VerfasserIn]
• Verfasst von: Steinfeld, Robert [VerfasserIn]
• Verfasst von: Strozzi, Susi [VerfasserIn]
• Verfasst von: Weichselbaum, Annette [VerfasserIn]
• Verfasst von: Weitz, Marcus [VerfasserIn]
• Verfasst von: Ziegler, Andreas [VerfasserIn]
• Verfasst von: Wandinger, Klaus-Peter [VerfasserIn]
• Verfasst von: Leypoldt, Frank [VerfasserIn]
• Verfasst von: Bien, Christian G. [VerfasserIn]
• Titel: CASPR2 autoimmunity in children expanding to mild encephalopathy with hypertension
• Verf.angabe: Steffen Syrbe, MD, Georg M. Stettner, MD, Julien Bally, MD, Ingo Borggraefe, MD, Corinna I. Bien, MD, Ruxandra Iancu Ferfoglia, MD, Peter Huppke, MD, Jan Kern, MD, Tilman Polster, MD, Elisabeth Probst-M ̈uller, MD, PhD, Silvia Schmid, MD, Robert Steinfeld, MD, Susi Strozzi, MD, Annette Weichselbaum, MD, Marcus Weitz, MD, Andreas Ziegler, MD, Klaus-Peter Wandinger, MD, Frank Leypoldt, MD, and Christian G. Bien, MD
• E-Jahr: 2020
• Jahr: May 18, 2020
• Umfang: 12 S.
• Fussnoten: Gesehen am 07.09.2020
• Titel Quelle: Enthalten in: Neurology
• Ort Quelle: Philadelphia, Pa. : Wolters Kluwer, 1951
• Jahr Quelle: 2020
• Band/Heft Quelle: 94(2020), 22, Seite e2290-e2301
• ISSN Quelle: 1526-632X
• DOI: doi:10.1212/WNL.0000000000009523
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 172897514X

Abstract

OBJECTIVE: To delineate autoimmune disease in association with contactin-associated protein 2 (CASPR2) antibodies in childhood, we reviewed the clinical phenotype of children with CASPR2 antibodies. - METHODS: Retrospective assessment of patients recruited through laboratories specialized in autoimmune CNS disease. - RESULTS: Ten children with serum CASPR2 antibodies were identified (age at manifestation 18 months to 17 years). Eight children with CASPR2 antibody titers from ≥1:160 to 1:5,120 had complex autoimmune diseases with an age-dependent clinical phenotype. Two children with structural epilepsy due to CNS malformations harbored nonspecific low-titer CASPR2 antibodies (serum titers 1:80). The clinical symptoms of the 8 children with high-titer CASPR2 antibodies were general weakness (8/8), sleep dysregulation (8/8), dysautonomia (8/8) encephalopathy (7/8), neuropathic pain (7/8), neuromyotonia (3/8), and flaccid paresis (3/8). Adolescents (3/8) showed pain, neuromyotonia, and encephalopathy, whereas younger children (5/8) displayed severe hypertension, encephalopathy, and hormonal dysfunction mimicking a systemic disease. No tumors were identified. Motor symptoms remitted with immunotherapy. Mild behavioral changes persisted in 1 child, and autism spectrum disorder was diagnosed during follow-up in a young boy. - CONCLUSION: High-titer CASPR2 antibodies are associated with Morvan syndrome in children as young as 2 years. However, CASPR2 autoimmunity mimics systemic disease and hypertensive encephalopathy in children younger than 7 years. The outcome following immunotherapy was mostly favorable; long-term behavioral impairment may occur in younger children.